Hereditary Breast and Gynecological Cancer Panel
Use
This test is intended for individuals with a clinical or suspected diagnosis of hereditary breast, ovarian, pancreatic, and prostate cancer syndrome or Lynch syndrome. It is particularly relevant for those with early-onset cancer diagnosed before age 50, individuals of Ashkenazi Jewish ancestry with a personal or family history of breast/ovarian cancer, and individuals with multiple first-, second-, and third-degree family members with related cancer diagnoses.
Special Instructions
Not provided.
Limitations
While the panel targets 19 specific genes related to hereditary breast and gynecological cancers, there may be limitations in detecting certain types of mutations or variants not covered by the NGS and CNV methodologies employed. Sensitivity of certain regions may be affected by the technical constraints of the sequencing platform.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided